Tobacco Cost of Illness Studies: A Systematic Review.


Journal

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
ISSN: 1469-994X
Titre abrégé: Nicotine Tob Res
Pays: England
ID NLM: 9815751

Informations de publication

Date de publication:
17 04 2020
Historique:
received: 24 09 2018
accepted: 06 03 2019
pubmed: 16 3 2019
medline: 29 9 2020
entrez: 16 3 2019
Statut: ppublish

Résumé

To identify studies reporting costs arising from tobacco use and detail their (1) economic approaches, (2) health outcomes, and (3) other cost areas included. We searched PubMed, Scopus, Cochrane Library, EconLit, and Google Scholar for studies published between 2008 and April 2018 in English. Eligible articles reported tobacco-related costs and included all tobacco-using populations (multinational, national, subpopulations, and involuntary smokers). All economic approaches that resulted in monetary outcomes were included. We reported USD or converted local currencies to USD. Two health economists extracted and two researchers independently reviewed the data. From 4083 articles, we reviewed 361 abstracts and examined 79 full-texts, with 63 (1.6%) deemed eligible. There were three multinational, thirty-four national, twenty-one subpopulation or condition(s)-specific analyses, and five evaluating involuntary smoking. The diverse approaches and outcomes precluded integrating costs, but these were substantial in all studies. For instance, about USD 1436 billion in global health expenditures and productivity losses in 2012 and USD 9 billion in lost productivity in China, Brazil, and South Africa in 2012. At the national level, costs ranged from USD 4665 in annual per respondent health expenses (Germany 2006-2008) to USD 289-332.5 billion in medical expenses (United States 1964-2014). Despite wide variations in the methods used, the identified costs of tobacco are substantial. Studies on tobacco cost-of-illness use diverse methods and hence produce data that are not readily comparable across populations, time, and studies, precluding a consistent evidence-base for action and measurement of progress. Recommendations are made to improve comparability. In addition to the health and financial costs to individual smokers, smoking imposes costs on the broader community. Production of comparable estimates of the societal cost of tobacco use is impaired by a plethora of economic models and inconsistently included costs and conditions. These inconsistencies also cause difficulties in comparing relative impacts caused by differing factors. The review systematically documents the post-2007 literature on tobacco cost-of-illness estimations and details conditions and costs included. We hope this will encourage replication of models across settings to provide more consistent data, able to be integrated across populations, over time, and across risk factors.

Identifiants

pubmed: 30874290
pii: 5381143
doi: 10.1093/ntr/ntz038
doi:

Substances chimiques

Tobacco Smoke Pollution 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

458-465

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved.For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Marshall Makate (M)

School of Public Health, Faculty of Health Sciences, Curtin University, Perth, WA, Australia.

Steve Whetton (S)

SA Centre for Economic Studies, University of Adelaide, Adelaide, SA, Australia.

Robert J Tait (RJ)

National Drug Research Institute, Faculty of Health Sciences, Curtin University, Perth, WA, Australia.

Tania Dey (T)

SA Centre for Economic Studies, University of Adelaide, Adelaide, SA, Australia.

Michelle Scollo (M)

Quit Victoria, Cancer Council Victoria, Melbourne, VIC, Australia.

Emily Banks (E)

National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT, Australia.

Richard Norman (R)

School of Public Health, Faculty of Health Sciences, Curtin University, Perth, WA, Australia.

Ken Pidd (K)

National Centre for Education and Training on Addiction, Flinders University, Adelaide, SA, Australia.

Ann M Roche (AM)

National Centre for Education and Training on Addiction, Flinders University, Adelaide, SA, Australia.

Steven Allsop (S)

National Drug Research Institute, Faculty of Health Sciences, Curtin University, Perth, WA, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH